Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT01470274
First received: November 9, 2011
Last updated: July 28, 2016
Last verified: July 2016

November 9, 2011
July 28, 2016
November 2011
January 2012   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01470274 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients
Safety of the CO-rebreathing Method in Stable Coronary Artery Disease and COPD Patients
The primary objective is to establish the safety of the CO-rebreathing method for measuring total blood and plasma volume in CAD patients. The working hypothesis is that the CO-rebreathing method is safe in use with coronary artery disease patients and that it does not cause myocardial ischemia or cardiovascular damage.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Blood samples
Non-Probability Sample
Stable, optimally medicated coronary artery disease and COPD patients with LVEF ≥ 0.40 will be recruited
  • Cardiovascular Disease
  • Chronic Obstructive Pulmonary Disease
Not Provided
Not Provided
Karlsen T, Leinan IM, Aamot IL, Dalen H, Støylen A. Safety of the CO-Rebreathing Method in Patients with Coronary Artery Disease. Med Sci Sports Exerc. 2016 Jan;48(1):33-8. doi: 10.1249/MSS.0000000000000729.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
18
February 2012
January 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Stable coronary artery disease
  • Stable COPD
  • Optimal medication

Exclusion Criteria:

  • Unstable disease
  • co-morbidities
Both
18 Years to 75 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Norway
 
NCT01470274
2011/1792
No
Not Provided
Not Provided
Norwegian University of Science and Technology
Norwegian University of Science and Technology
Not Provided
Principal Investigator: Trine Karlsen, PhD Norwegian University of Science and Technology
Norwegian University of Science and Technology
July 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP